Medical
Capstan Medical said its investigational robot was used in the first U.S. transcatheter mitral valve replacement, performed on Nov. 9 in Cincinnati.
A dated step forward on the record · Company-reported · Sets Compass robotic system's stage
What the source says
“was part of an FDA-authorized early feasibility study”
What it means
This is what holds Compass at Pilot, stage 3 of 5. The company says the case ran inside an FDA-authorized early feasibility study, so it is still early testing. Every milestone on our record is company-reported. The March 2025 promise of a pivotal trial in 2026 is still pending, and nothing here shows it has started. Every other robot we list in surgical and medical is at stage 5.
Compass robotic system, from Capstan Medical, is at stage 3 of 5 on our ladder: pilot. This event is one of the milestones that placed it there. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: A surgeon in the operating room controls it; it doesn't operate on its own.
Written with AI from our record of Compass robotic system and checked against it: every figure appears in that record.
